Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 30;14(23):2702.
doi: 10.3390/diagnostics14232702.

Longitudinal Study of Patients with Connective Tissue Disease-Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab

Affiliations

Longitudinal Study of Patients with Connective Tissue Disease-Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab

Yan Li et al. Diagnostics (Basel). .

Abstract

Background/Objective: To investigate the effect of mycophenolate mofetil (MMF) and rituximab (RTX) on pulmonary function test (PFT) results in a mixed cohort of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), longitudinally followed up for 1 year in a single academic center. Methods: Patients with CTD-ILD were identified in electronic medical records from 1 January 2009 to 30 April 2019. Prescribed MMF and RTX doses, dosage changes, and therapy plans were analyzed individually with improvement in PFT outcomes determined using multivariable linear regression models during 12-month follow-up. Results: Forty-seven patients with CTD-ILD, treated with MMF, RTX, or both, were included. Patients on combined MMF and RTX had worse PFT outcomes at baseline compared with patients on monotherapy. Substantial improvement was observed among all PFT outcomes from baseline to 12 months, regardless of medication dosage or therapy plans. The diffusing capacity of the lungs for carbon monoxide (DLCO) worsened by an average of 7.21 mL/(min*mmHg) (95% CI, 4.08-10.33; p < 0.001) among patients on RTX compared to combined therapy. Patients on higher doses of MMF at baseline experienced an average increase of 0.93 (95% CI, 0.04-1.82) units in DLCO from baseline to 6 months (p = 0.04) and a 2.79% (95% CI, 0.61-4.97%) increase in DLCO from 6 to 12 months (p = 0.02) within patients on concurrent RTX at 6-month follow-up. Conclusions: The treatment of CTD-ILD with MMF and/or RTX was associated with overall improvement in PFT outcomes. Combined therapy resulted in significant improvements in DLCO compared with monotherapy. Higher doses of MMF also provided greater improvements in DLCO.

Keywords: connective tissue diseases; immunosuppressive agents; interstitial lung disease; respiratory function tests.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Fischer A., Du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380:689–698. doi: 10.1016/S0140-6736(12)61079-4. - DOI - PubMed
    1. Marigliano B., Soriano A., Margiotta D., Vadacca M., Afeltra A. Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis. Autoimmun. Rev. 2013;12:1076–1084. doi: 10.1016/j.autrev.2013.05.001. - DOI - PubMed
    1. Zamora-Legoff J.A., Krause M.L., Crowson C.S., Ryu J.H., Matteson E.L. Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin. Rheumatol. 2016;35:2585–2589. doi: 10.1007/s10067-016-3357-z. - DOI - PubMed
    1. Mira-Avendano I., Abril A., Burger C.D., Dellaripa P.F., Fischer A., Gotway M.B., Lee A.S., Lee J.S., Matteson E.L., Yi E.S., et al. Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clin. Proc. 2019;94:309–325. doi: 10.1016/j.mayocp.2018.09.002. - DOI - PubMed
    1. Fischer A., Antoniou K.M., Brown K.K., Cadranel J., Corte T.J., du Bois R.M., Lee J.S., Leslie K.O., Lynch D.A., Matteson E.L., et al. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur. Respir. J. 2015;46:976–987. doi: 10.1183/13993003.00150-2015. - DOI - PubMed

LinkOut - more resources